LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Core Viewpoint - LENZ Therapeutics is focused on the commercialization of VIZZ™, the first FDA-approved aceclidine-based eye drop for treating presbyopia, and will participate in several upcoming investor and medical conferences to present VIZZ [1][11]. Company Information - LENZ Therapeutics is headquartered in San Diego, California, and is dedicated to providing access to VIZZ globally through licensing partnerships [11]. - The company is targeting a significant market, with presbyopia affecting approximately 1.8 billion people worldwide and 128 million in the United States [11]. Product Details - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [7]. - The product works by causing contraction of the iris sphincter muscle, creating a pinhole effect that enhances depth of focus [7]. Upcoming Conferences - LENZ Therapeutics will participate in several conferences, including: - Citi's 2025 BioPharma Back to School Conference on September 2-3, 2025, in Boston, MA [2]. - Cantor Global Healthcare Conference on September 4, 2025, in New York City, NY [2]. - H.C. Wainwright 27 Annual Global Investment Conference on September 9, 2025, in New York City, NY [2]. - Morgan Stanley 23 Annual Global Healthcare Conference on September 10, 2025, in New York City, NY [3]. - Academy 2025 on October 8-9, 2025, in Boston, MA, featuring presentations on the efficacy of VIZZ [4].